Replimune Group (NASDAQ:REPL) Shares Gap Up – Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL) shares gapped up prior to trading on Wednesday . The stock had previously closed at $8.78, but opened at $9.49. Replimune Group shares last traded at $9.3720, with a volume of 462,393 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have weighed in on REPL. Leerink Partners reiterated a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. BMO Capital Markets cut shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. Piper Sandler downgraded shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price objective for the company. in a report on Friday, April 10th. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 price target for the company in a research report on Friday, May 29th. Seven analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Replimune Group has an average rating of “Reduce” and an average price target of $4.88.

Replimune Group Price Performance

The firm has a market cap of $841.39 million, a P/E ratio of -2.96 and a beta of 0.91. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The company’s 50-day moving average is $5.35 and its two-hundred day moving average is $7.25.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in REPL. International Assets Investment Management LLC bought a new stake in shares of Replimune Group during the 4th quarter worth $29,000. Russell Investments Group Ltd. grew its position in Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after acquiring an additional 7,569 shares during the last quarter. CWM LLC raised its stake in Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after acquiring an additional 2,886 shares in the last quarter. Essential Partners LLC raised its stake in Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Replimune Group by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after acquiring an additional 6,873 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.